Navigation Links
Enteris BioPharma Forms Scientific Advisory Board to Enhance Leadership in Oral Delivery of Peptide and Small Molecule Drugs
Date:12/3/2013

BOONTON, N.J., Dec. 3, 2013 /PRNewswire/ -- Enteris BioPharma, Inc., an industry leader in innovative oral dosage formulations, today announced the appointment of Steven J. Brickner, Ph.D., Jonathan Chernoff, MD, Ph.D., and Waleed Danho, Ph.D to the company's Scientific Advisory Board.

Highly regarded scientists and thought leaders, Drs. Brickner, Chernoff and Danho will work with Enteris' executive team to maximize the potential of its proprietary oral delivery technology platform and the development of orally delivered peptide and small molecule drugs.

Brian Zietsman, President and CFO of Enteris BioPharma, commented, "We are very honored to welcome such esteemed scientific minds as Drs. Brickner, Chernoff and Danho to our inaugural Scientific Advisory Board.  Already in the short time that Drs. Brickner, Chernoff and Danho have been advising our company and working with our proprietary oral delivery technology platform, they have provided invaluable input on potential development opportunities and therapeutic targets.  We greatly look forward to benefitting from their unparalleled acumen as Enteris seeks to become the industry leader in the oral delivery of peptides and difficult to deliver small molecule therapeutics."

With more than 100 combined years of industry and research experience, Drs. Brickner, Chernoff and Danho each offers areas of specialization that will help to shape Enteris' development strategy and therapeutic pursuits. 

Dr. Brickner joins Enteris' Scientific Advisory Board as an expert in synthetic organic/medicinal chemistry and the discovery of novel antibacterial agents.  While at Upjohn, Dr. Brickner was the co-inventor of Zyvox® (linezolid), an oxazolidinone that holds the #1 rank among all
'/>"/>

SOURCE Enteris BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Enteris BioPharma and Nordic BioSciences KeyBioScience Enter Strategic Licensing Agreement to Develop Metabolic Peptides Using Enteris Proprietary Oral Drug Delivery and Manufacturing Platform
2. Enteris BioPharma Initiates Business and Development Activities Targeting Oral Delivery of Peptides and Small Molecule Therapeutics
3. Therapure Biopharma Inc. has Acquired Plasma Protein Purification Technology From Upfront Chromatography A/S
4. PDL BioPharma to Present at the 25th Annual Piper Jaffray Healthcare Conference
5. UCLA Venture Capital Fund Selects KYTHERA Biopharmaceuticals CEO Keith Leonard for First Annual Entrepreneurial Achievement Award
6. IPO, Earnings & Corporate Developments: Twitter, Vale SA, OCZ Technology Group, Radian Group, Keryx Biopharmaceuticals
7. TransCelerate BioPharma Inc. Launches Second Year Initiatives, Expands Membership and Achieves Milestones for Original Projects
8. Biopharmaceuticals - A Global Market Overview
9. Can-Fite BioPharma to Conduct European Road Show
10. MGB Biopharma to Present at Bio-Europe 2013
11. Sanofi Adopts Genedata Biologics for Integrated Biopharma R&D Process Support
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA theory ... of these latent viruses is the Epstein Barr Virus (EBV), ... arthritis (RA) is a chronic inflammatory disease that destroys the ... that RA patients have high concentrations of EBV DNA in ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 As pet owners drew ... doubt many of them wrote: "Take better care of my furry ... even designer clothes and top-brand carrying cases to take the little ... parents might also feel compelled to buy some pricey toys at ...
(Date:1/14/2014)... 2014 In recent years, growing suspicion ... in product development and promotion has led to unprecedented ... fueled by concerns about the insidious impact of commercialization ... spectacular fines to the world’s biggest pharmas for illegal ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... Laboratories, pathologist, Ronald L. Weiss, MD, MBA, FCAP, received ... Pathologists at CAP ,11, the organization,s annual meeting, held ... the award honors members "who have made a broad ... of pathology." (Logo: http://photos.prnewswire.com/prnh/20110915/SF69370LOGO ) ...
... 2011 NewCardio, Inc., (OTC BB: NWCI) a cardiovascular ... Clinilabs, will utilize QTinno®, NewCardio,s automated cardiac safety solution, ... new drug under development for a central nervous system ... one important aspect of the trial. Clinilabs, ...
... 2011 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), ... announced financial results for the third quarter of 2011. For ... net loss of $4.6 million, or $0.10 per share, as ... per share, for the third quarter of 2010. As of ...
Cached Biology Technology:ARUP Laboratories' Pathologist, Ronald L. Weiss, MD, Honored With Lifetime Achievement Award for Contributions to Patient Care and Pathology 2Clinilabs will Conduct Phase 1 Trial Using QTinno® 2Clinilabs will Conduct Phase 1 Trial Using QTinno® 3Clinilabs will Conduct Phase 1 Trial Using QTinno® 4Clinilabs will Conduct Phase 1 Trial Using QTinno® 5Orexigen® Therapeutics Reports Third Quarter Financial Results 2Orexigen® Therapeutics Reports Third Quarter Financial Results 3Orexigen® Therapeutics Reports Third Quarter Financial Results 4Orexigen® Therapeutics Reports Third Quarter Financial Results 5
(Date:4/17/2014)... Kessler Foundation has been named awardee of a ... of Defense Spinal Cord Injury Research Program. Gail ... randomized, double-blinded, controlled, multi-site clinical trial, which will ... after spinal cord injury. Dr. Forrest is assistant ... Kessler Foundation. Two additional sites will participate - ...
(Date:4/17/2014)... in about one per eight hundred births, Down syndrome ... genetic cause of intellectual disability. It results from a ... third copy of chromosome 21 (1% of the human ... team in the Department of Genetic Medicine and Development ... published in Nature , shed light on how ...
(Date:4/17/2014)... about eight years ago, Katia Silvera , a postdoctoral ... were on a field trip in a mountainous area in ... never seen before. , Unable to identify it, they contacted ... turned out to be an unnamed species. So Carnevali recently ... "Lophiaris" is the genus name, comprising about 40 species in ...
Breaking Biology News(10 mins):Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3
... Angeles, London, New Delhi, Singapore and Washington DC (16 September, ... Journal of Dental Biomechanics (JDB), the second open access ... and the Hindawi Publishing Corporation. The Journal of ... to the study of biomechanics as it relates to dentistry. ...
... More than 125 years ago Charles Darwin first reported ... not the day and this week, scientists are reporting ... These rhythmic growth spurts, and the ability of plants to ... involved in circadian rhythms the "biological clock" genes that ...
... he discovered a gene that controls innate fear in ... the same gene promotes "helicopter mom" behavior in mice. ... female animals to protect newborn pups and interact cautiously ... concentrated in the amygdala, a key region of the ...
Cached Biology News:SAGE-Hindawi launch Journal of Dental Biomechanics 2'Biological clock' genes control plant growth 2No helicopter moms among Rutgers mutant mice 2No helicopter moms among Rutgers mutant mice 3
... ISO 9001:2000 Certified USDA Research Registered OLAW ... Training AALAS Certified Technicians ... GLP Documentation Upon Request Focus ... for all your custom immunology service needs. ...
Human IL-17D Affinity Purified Polyclonal Ab...
BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L...
... peptide derived from an internal region of ... of rapamycin FRAP RAFT1 RAPT1). Specificity: ... On Western blots it identifies the target ... (positive control: HEK293 cell lysates). Based on ...
Biology Products: